FDA Approves ADRENALIN — Par Health USA, LLC

Par Health USA, LLC has secured FDA approval for injection, epinephrine, intended for the management of severe allergic reactions, historically opening the market for older-formulation generic epinephrine products under NDA 204640. This regulatory clearance broadens the landscape for adrenergic antagonists, positioning Par Health to compete against established market leaders in the adrenaline segment.